NHS officials in England have made an improved two-year pricing deal to Vertex Pharmaceuticals in a bid to give patients access to cystic fibrosis (CF) medicines.
Children in England with the rare muscle wasting disease spinal muscular atrophy (SMA) will get access to Biogen’s super-expensive new drug Spinraza after the manufacturer struck a deal wit
